Wall Street Prescribes AstraZeneca a 9% Humility Tax After Wainua’s Clinical Whiff

Common side effects of buying AstraZeneca include dizziness, elevated heart rate, and an unexplained 9% reduction in net worth.

Big Pharma rarely fumbles the football... but when it does, shareholders recover it with their face.

AstraZeneca woke up to a depressing 9% discount after one of its late-stage heart drug trials failed to deliver the result management had spent months sounding confident about. 

The guilty party was Wainua, a drug AstraZeneca has been testing to see whether it could reduce deaths and repeat heart-related emergencies in patients suffering from a rare heart disease called ATTR-CM.

Unfortunately… the placebo remained undefeated.

After tracking patients for 140 weeks, the trial failed to hit its primary endpoint, meaning Wainua didn't show a statistically significant improvement over standard treatment for the overall patient population. And investors wasted approximately zero seconds reaching for the sell button.

Oddly enough, the failed trial isn't even the biggest concern. Analysts aren't freaking out because AstraZeneca suddenly forgot how to sell drugs on CNN and Fox News commercials… They're freaking out because management sounded so confident this thing was going to work.

Jefferies said the failed trial probably doesn't derail AstraZeneca's ambitious plan to hit $80 billion in annual sales by 2030. In fact, they only shaved about $2.5 billion off their risk-adjusted sales estimates for the drug.

It’s the same reaction Conor McGregor will get from UFC fans if he gets dog-walked by Max Holloway after all the talk.

The “suits” expected a knockout… instead, one of pharma's most reliable overachievers confidently walked into a rake.

For the past 14 years under CEO Pascal Soriot, AstraZeneca has built a reputation for being the medical student who everyone else tries to copy on the test. The amount of clinical disasters you can count on one hand.

So when one of its marquee late-stage studies faceplants... people start wondering whether management got a little too high on its own supply.

I personally don’t think the story is quite as disastrous as the stock chart makes it look. Wainua is already approved for treating nerve-related forms of the disease, so today's results don't affect its existing license.

The thing is... Wainua may have been fighting with one hand tied behind its back. More than half the patients were already taking another treatment before the trial even kicked off, and another 24% started taking it during the study.

That's a tough environment to prove your drug delivers even more benefit. Sure enough, when researchers looked only at patients who weren't already on those treatments, Wainua actually reduced deaths and heart-related events.

Unfortunately for shareholders… This isn't a kids soccer league in America. Clinical trials don't hand out participation trophies. The primary endpoint is the primary endpoint. Miss it, and the market usually hands you a one-way ticket to the shadow realm.

Meanwhile, AstraZeneca wasn't the only casualty. Ionis Pharmaceuticals, which co-develops Wainua in the U.S., saw its shares crater 20% in premarket trading.

On the flip side, Alnylam's ATTR-CM drug Amvuttra suddenly looked a whole lot prettier, sending its shares soaring around 17% as investors realized there was now one less shark in the tank.

Analysts now expect AstraZeneca shares could stay in the penalty box until the company's next major catalyst arrives, with many investors likely waiting for results from its upcoming AVANZAR cancer trial before rebuilding confidence. 

In my humble opinion, this could be a good dip-buying opportunity. Especially since historically speaking, AstraZeneca has a very low chance of failing two clinical trials back to back. (At least until I just said that.)

At the time of publishing this article, Stocks.News doesn’t hold positions in companies mentioned in the article.